Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

By Yuichiro Ohigashi, M. Sho, Yukishige Yamada, Y. Tsurui, K. Hamada, N. Ikeda, T. Mizuno, R. Yoriki, H. Kashizuka, K. Yane and 5 more. Clinical Cancer Research, 2005

770 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/7259640c2cc612884fd6beedb30f11cebda56814

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lieping Chen
2. G. Freeman
3. Arlene H. Sharpe
4. J. Wolchok
5. W. Zou
6. Padmanee Sharma
7. Loise M. Francisco
8. V. Kuchroo

In Oncology

1. Lieping Chen
2. G. Freeman
3. W. Zou
4. Arlene H. Sharpe
5. J. Wolchok
6. Padmanee Sharma
7. Loise M. Francisco
8. V. Kuchroo

Citations in the corpus

• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. (2006, background): “Furthermore, a strong link between B7-H1 expression by cancer cells or tumor-infiltrating lymphocytes (TIL) and the patient’s clinicopathological status has been shown in non–small cell lung carcinoma [21], renal cell carcinoma [22], and esophageal cancer [ 23 ].”
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (2009, background): “PD-L1 is expressed on a wide variety of tumors, and high levels of PD-L1 expression strongly correlate with unfavorable prognosis in several cancers (Dong et al., 2002; Iwai et al., 2002; Strome et al., 2003; Konishi et al., 2004; Thompson et al., 2004; Blank et al., 2005; Hirano et al., 2005; Ohiga”
• PD-L1 Expression in Triple Negative Breast Cancer (2014, positive): “PD-L1 is not expressed on normal epithelial tissues but is expressed on many cancers including renal cell carcinoma (20, 26), pancreatic cancer (27), ovarian cancer (28), gastric cancer (29), esophageal cancer (30), and hepatocellular carcinoma (31).”
• PD-L1 expression in human cancers and its association with clinical outcomes (2016, positive): “esophageal cancer Positive correlation between PD-L1 expression and poor prognosis in EC was reported by two studies.(36,37) Ohigashi et al(36) selected 10% as cut-off value and illustrated that 18 of 41 positive cases express PD-L1 or PD-L2 on the plasma membrane and in the cytoplasm of cancer cell”
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Tumor tissues of RCC (72) and esophageal, gastric (73, 74), and ovarian (75) cancers show that PD-L1 expression is an indicator of poor prognosis for patient survival.”
• Inhibitory B7-family molecules in the tumour microenvironment (2008, background): “Similarly, B7-H1 expression was also identified as a poor prognostic factor in patients with oesophageal, gastri”